Arsenic trioxide [1], hypomagnesemia ---> SmPC of [1] of EMA
Patients who are receiving, or who have received, medicinal products known to cause hypokalemia or hypomagnesaemia, may be at higher risk for torsade de pointes.
Azithromycin [1], hypomagnesemia ---> SmPC of [1] of eMC
Azithromycin should be used with caution in patients currently receiving treatment with other active substances that cause electrolyte imbalance
Cardiac glycosides, hypomagnesemia
The co-administration of cardiac glycosides and drugs that cause potassium and magnesium loss may enhance the effects and adverse reactions of cardiac glycosides
Citalopram [1], hypomagnesemia ---> SmPC of [1] of eMC
Caution is warranted for concomitant use of citalopram and hypokalaemia/hypomagnesaemia inducing medicinal products as these conditions increase the risk of malignant arrhythmias
Dasatinib [1], hypomagnesemia ---> SmPC of [1] of EMA
In vitro data suggest that dasatinib has the potential to prolong cardiac ventricular repolarisation (QT Interval). Dasatinib should be administered with caution to patients who have or may develop prolongation of QTc.
Delamanid [1], hypomagnesemia ---> SmPC of [1] of EMA
Treatment with delamanid should not be initiated in patients with risk factors like electrolyte disturbances, particularly hypokalaemia, hypocalcaemia or hypomagnesaemia unless the possible benefit is considered to outweigh the potential risks.
Digital glycosides, hypomagnesemia ---> SmPC of [metildigoxin] of eMC
It should be paid special attention when digitalis glycosides are combined with drugs that induce hypomagnesemia
Digitoxin, hypomagnesemia
Increased effect of digitoxin and risk of digitoxin intoxication due to drug-induced hypokaliemia and hypomagnesemia
Digoxin [1], hypomagnesemia ---> SmPC of [1] of eMC
Agents causing hypokalaemia or intracellular potassium deficiency may cause increased sensitivity to digoxin
Doxylamine, hypomagnesemia
Concomitant use of doxylamine with drugs that cause electrolyte imbalance should be avoided
Dronedarone [1], hypomagnesemia ---> SmPC of [1] of EMA
Since antiarrhythmic medicinal products may be ineffective or may be arrhythmogenic in patients with hypokalemia, any potassium or magnesium deficiency should be corrected before initiation and during dronedarone therapy.
Droperidol [1], hypomagnesemia ---> SmPC of [1] of eMC
To prevent QT prolongation, caution is necessary when patients are taking medicinal products likely to induce electrolyte imbalance
Escitalopram [1], hypomagnesemia ---> SmPC of [1] of eMC
Caution is warranted for concomitant use of escitalopram with hypokalaemia/hypomagnesaemia inducing medicinal products as these conditions increase the risk of malignant arrhythmias
Hypomagnesemia, lansoprazole [2] ---> SmPC of [2] of eMC
Severe hypomagnesaemia has been reported in patients treated with PPIs like lansoprazole for at least three months, and in most cases for a year.
Hypomagnesemia, lapatinib [2] ---> SmPC of [2] of EMA
Caution should be taken if lapatinib is administered to patients with conditions that could result in prolongation of QTc
Hypomagnesemia, levacetylmethadol
Medicinal products known to induce low blood salts must never be taken during the course of levacetylmethadol treatment
Hypomagnesemia, methadone [2] ---> SmPC of [2] of eMC
Cases of QT interval prolongation and torsade de pointes have been reported during methadone treatment, particularly at high doses (> 100 mg/d). Methadone should be administered with caution to patients at risk of development of prolonged QT interval
Hypomagnesemia, metildigoxin
It should be paid special attention when digitalis glycosides are combined with drugs that induce hypomagnesemia
Hypomagnesemia, ofloxacin [2] ---> SmPC of [2] of eMC
Caution should be taken when using fluoroquinolones, including ofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example uncorrected electrolyte imbalance (e.g. hypokalaemia, hypomagnesaemia)
Hypomagnesemia, pimozide
The co-administration of pimozide with medicinal products that cause hypomagnesemia should be avoided
Hypomagnesemia, posaconazole [2] ---> SmPC of [2] of EMA
Electrolyte disturbances should be monitored and corrected as necessary before and during posaconazole therapy.
Hypomagnesemia, proton pump inhibitors ---> SmPC of [lansoprazole] of eMC
Severe hypomagnesaemia has been reported in patients treated with PPIs for at least three months, and in most cases for a year.
Hypomagnesemia, quinolones ---> SmPC of [ofloxacin] of eMC
Caution should be taken when using fluoroquinolones, including ofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example uncorrected electrolyte imbalance (e.g. hypokalaemia, hypomagnesaemia)
Hypomagnesemia, risperidone [2] ---> SmPC of [2] of eMC
Caution is advised when prescribing risperidone with medicines causing electrolyte imbalance
Hypomagnesemia, roxithromycin
Caution is warranted for concomitant use of roxitromycin with hypokaliemia or hypomagnesemia
Hypomagnesemia, selpercatinib [2] ---> SmPC of [2] of EMA
Hypokalaemia, hypomagnesaemia and hypocalcaemia should be corrected prior to initiating selpercatinib and during treatment.
Hypomagnesemia, sorafenib [2] ---> SmPC of [2] of EMA
Sorafenib has been shown to prolong the QT/QTc interval, which may lead to an increased risk for ventricular arrhythmias. Use sorafenib with caution in patients who have, or may develop prolongation of QTc
Hypomagnesemia, terfenadine
Hypokalaemia or other electrolyte imbalance increases the risk of ventricular arrhythmias with terfenadine.
Hypomagnesemia, terlipressin
Terlipressin can cause ventricular arrhythmias. The combination with drugs that can origin electrolyte disorders should be done with extreme caution
Hypomagnesemia, tolterodine [2] ---> SmPC of [2] of eMC
Tolterodine should be used with caution in patients with risk factors for QT-prolongation
Hypomagnesemia, zoledronic acid [2] ---> SmPC of [2] of EMA
Attention should be paid to the possibility of hypomagnesaemia developing during treatment.